

Global Speaker Development Meeting

Barcelona, Spain
26 – 27 January 2008

DRAFT Agenda

Saturday, 26 January

- | | |
|---------------|---|
| 7.00 – 8.00 | Breakfast |
| 8.00 – 8.15 | Welcome and Introduction
<i>Marina Brodsky, PhD</i>
<i>Pfizer Inc</i> |
| 8.15 – 8.30 | Discussion of Fesoterodine and Tolterodine in the Marketplace
<i>Jorg Bruggemann</i>
<i>Pfizer Inc</i> |
| 8.30 – 9.15 | Improving upon the OAB Gold Standard: Opportunity for Dose Individualisation
<i>Christopher Chapple, MD, BSc, FRCS, FEBU</i> <ul style="list-style-type: none">• Question & Answer Session |
| 9.15 – 10.00 | The Link between Fesoterodine and Tolterodine: Pre-clinical and Early Clinical Data
<i>Martin Michel, MD</i> <ul style="list-style-type: none">• Question & Answer Session |
| 10.00 – 10.15 | Break |
| 9.45 – 12.00 | Fesoterodine Efficacy, Safety and Tolerability, Demonstrated in Phase 3 Studies <ul style="list-style-type: none">• Phase 3 Study Design and Efficacy Results from the US Study (SP584)
<i>Eric Rovner, MD</i>• Efficacy Results from the International Study (SP583) and Combined Phase 3 Safety and Tolerability Results
<i>Andrea Tubaro, MD, PhD</i>• Question & Answer Session |
| 12.00 – 13.00 | Lunch |

Saturday, 26 January (cont'd)

- | | |
|----------------------|---|
| 13.00 – 14.00 | Fesoterodine Promotional Slide Kit <ul style="list-style-type: none">• Fesoterodine Profile Established in Pre-clinical and Phase 1 and 2 Clinical Trials
<i>Klaus-Peter Jünemann, MD, PhD</i>• Fesoterodine Efficacy, Safety and Tolerability as demonstrated in Phase 3 Trials
<i>Paul Abrams, MD, FRCS</i> |
| 14.00 – 14.30 | Question & Answer Session |
| 14.30 – 14.45 | Overview of Case Studies
<i>Sender Herschorn, MD, FRCSC</i> |
| 14.45 – 15.15 | Case Study 1
56 Year Old Female – Treatment Naive
Question & Answer Session
<i>Sender Herschorn, MD, FRCSC</i> |
| 15.15 – 15.45 | Case Study 2
72 Year Old Male – Treatment Naive
Question & Answer Session
<i>Klaus-Peter Jünemann, MD, PhD</i> |
| 15.45 – 16.15 | Case Study 3
63 Year Old Male - Previously Treated
Question & Answer Session
<i>Klaus-Peter Jünemann, MD, PhD</i> |
| 16.15 – 16.30 | Overview of Sunday's Workshops and Closing Remarks
<i>Marina Brodsky, PhD</i>
<i>Pfizer Inc</i> |
| 19.30 | Dinner (offsite) |

Sunday, 27 January

7.30 – 8.15

Breakfast

8.15 – 8.30

Introduction to Day 2

Marina Brodsky, PhD

Pfizer Inc

8.30 – 9.00

Potential Applications of Nanotechnology in Urology

Iqbal S. Shergill, BSc, MB,BS, MRCS

Guest Speaker

9.15 – 12.00

Workshop Overview and Assignments

Presenter: Workshop Trainer

Workshop Sessions

Faculty Members:

Paul Abrams, MD, FRCS

Linda Cardozo, MD

Christopher Chapple, MD, BSc, FRCS, FEBU

Roger Dmochowski, MD

Sender Herschorn, MD, FRCSC

Klaus-Peter Jünemann, MD, PhD

Steven Kaplan, MD, FACS

David Sussman, DO, FACOS

Andrea Tubaro, MD, PhD

12.00 – 13.00

Lunch (Optional)

Departures